Trial Profile

A Multi-Center, Open-Label, Phase I, Dose-Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PTI 188 (Primary)
Indications Malignant melanoma
Focus Adverse reactions
Sponsors Cassava Sciences

Most Recent Events

03 Feb 2011 Survival results will be presented at the 2011 American Society of Clinical Oncology Meeting, according to a Pain Therapeutics media release.
31 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
23 Mar 2010 Positive efficacy results evaluating both phase I trials in patients with metastatic melanoma in Israel have been reported in a Pain Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com